復星醫藥(600196.SH):擬與包括關聯方在內的其他4方投資人設基金
格隆匯12月28日丨復星醫藥(600196.SH)公佈,2020年12月28日,公司控股子公司/企業南京復鑫、寧波復瀛與包括關聯方復星高科技在內的其他4方投資人簽訂《目標基金合夥協議》等,擬共同出資設立目標基金。目標基金將主要投資生物醫藥、醫療器械、生物材料、精準治療、體外診斷、醫療科技等領域參股型項目。目標基金計劃募集資金人民幣15億元,其中首輪擬募集資金人民幣10.101億元,各投資人認繳出資情況如下:

目標基金設立完成後,擬與復健基金管理公司簽訂《目標基金管理協議》,聘任復健基金管理公司為目標基金的基金管理人。
此次投資旨在通過對目標基金的投資,重點發掘具有前沿技術、創新產品和模式的優質標的,拓寬與生物醫藥、醫療器械、生物材料、精準治療等領域優秀企業合作的渠道,加強集團大健康產業佈局。此次投資完成後,目標基金將納入集團合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.